# Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases

> **NCT06683703** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Beijing Biostar Pharmaceuticals Co., Ltd.** · enrollment: 118 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer Patients with Brain Metastases

## Interventions

- **DRUG:** Utidelone combined with Bevacizumab
- **DRUG:** Utidelone
- **DRUG:** Utidelone combined with Bevacizumab
- **DRUG:** Utidelone combined with Bevacizumab

## Key facts

- **NCT ID:** NCT06683703
- **Lead sponsor:** Beijing Biostar Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-12-01
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 118 (ESTIMATED)
- **Last updated:** 2024-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06683703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06683703, "Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06683703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*